Literature DB >> 27864294

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Beiying Dai1,2,3, Michael Grau1,2, Mélanie Juilland4, Pavel Klener5,6, Elisabeth Höring7,8, Jan Molinsky5,6, Gisela Schimmack9, Sietse M Aukema10, Eva Hoster11,12, Niklas Vogt1,13, Annette M Staiger8,14, Tabea Erdmann1,2, Wendan Xu1,2, Kristian Erdmann1,2, Nicole Dzyuba1,2, Hannelore Madle1,2, Wolfgang E Berdel2,15, Marek Trneny6, Martin Dreyling11, Korinna Jöhrens16, Peter Lenz17, Andreas Rosenwald18, Reiner Siebert10,19, Alexandar Tzankov20, Wolfram Klapper13, Ioannis Anagnostopoulos16, Daniel Krappmann9, German Ott14, Margot Thome4, Georg Lenz1,2,15.   

Abstract

Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by poor clinical outcome. Recent studies revealed the importance of B-cell receptor (BCR) signaling in maintaining MCL survival. However, it remains unclear which role MALT1, an essential component of the CARD11-BCL10-MALT1 complex that links BCR signaling to the NF-κB pathway, plays in the biology of MCL. Here we show that a subset of MCLs is addicted to MALT1, as its inhibition by either RNA or pharmacologic interference induced cytotoxicity both in vitro and in vivo. Gene expression profiling following MALT1 inhibition demonstrated that MALT1 controls an MYC-driven gene expression network predominantly through increasing MYC protein stability. Thus, our analyses identify a previously unappreciated regulatory mechanism of MYC expression. Investigating primary mouse splenocytes, we could demonstrate that MALT1-induced MYC regulation is not restricted to MCL, but represents a common mechanism. MYC itself is pivotal for MCL survival because its downregulation and pharmacologic inhibition induced cytotoxicity in all MCL models. Collectively, these results provide a strong mechanistic rationale to investigate the therapeutic efficacy of targeting the MALT1-MYC axis in MCL patients.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27864294     DOI: 10.1182/blood-2016-05-718775

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

2.  Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

Authors:  Jimmy Lee; Liang Leo Zhang; Wenjun Wu; Hui Guo; Yan Li; Madina Sukhanova; Girish Venkataraman; Shengjian Huang; Hui Zhang; Mir Alikhan; Pin Lu; Ailin Guo; Natalie Galanina; Jorge Andrade; Michael L Wang; Y Lynn Wang
Journal:  Blood Adv       Date:  2018-08-28

3.  Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.

Authors:  Sietse M Aukema; Giorgio A Croci; Reiner Siebert; Wolfram Klapper; Susanne Bens; Kathrin Oehl-Huber; Rabea Wagener; German Ott; Andreas Rosenwald; Philip M Kluin; Eva van den Berg; Anneke G Bosga-Bouwer; Mels Hoogendoorn; Eva Hoster; Iris Bittmann; Inga Nagel; Eva M Murga Penas; Markus Kreuz; Julia Bausinger; Wilfried Belder; Ilske Oschlies; Martin J S Dyer; Sandrine Jayne
Journal:  Virchows Arch       Date:  2021-02-02       Impact factor: 4.064

4.  Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.

Authors:  Lorena Fontán; Qi Qiao; John M Hatcher; Gabriella Casalena; Ilkay Us; Matt Teater; Matt Durant; Guangyan Du; Min Xia; Natalia Bilchuk; Spandan Chennamadhavuni; Giuseppe Palladino; Giorgio Inghirami; Ulrike Philippar; Hao Wu; David A Scott; Nathanael S Gray; Ari Melnick
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

5.  Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.

Authors:  Pieter Van Vlierberghe; Steven Goossens; Tim Pieters; Sara T'Sas; Stijn Vanhee; André Almeida; Yasmine Driege; Juliette Roels; Wouter Van Loocke; Willem Daneels; Mathijs Baens; Arnaud Marchand; Maaike Van Trimpont; Filip Matthijssens; Julie Morscio; Kelly Lemeire; Béatrice Lintermans; Lindy Reunes; Patrick Chaltin; Fritz Offner; Jo Van Dorpe; Tino Hochepied; Geert Berx; Rudi Beyaert; Jens Staal
Journal:  J Exp Med       Date:  2021-08-18       Impact factor: 14.307

Review 6.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Authors:  Jan A Burger; Adrian Wiestner
Journal:  Nat Rev Cancer       Date:  2018-01-19       Impact factor: 60.716

7.  Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.

Authors:  Lorena Fontan; Rebecca Goldstein; Gabriella Casalena; Matthew Durant; Matthew R Teater; Jimmy Wilson; Jude Phillip; Min Xia; Shivem Shah; Ilkay Us; Himaly Shinglot; Ankur Singh; Giorgio Inghirami; Ari Melnick
Journal:  Blood       Date:  2021-02-11       Impact factor: 25.476

Review 8.  The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects.

Authors:  Lynh Nguyen; Peter Papenhausen; Haipeng Shao
Journal:  Genes (Basel)       Date:  2017-04-05       Impact factor: 4.096

9.  MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.

Authors:  Nakhle S Saba; Deanna H Wong; Georges Tanios; Jessica R Iyer; Patricia Lobelle-Rich; Eman L Dadashian; Delong Liu; Lorena Fontan; Erik K Flemington; Cydney M Nichols; Chingiz Underbayev; Hana Safah; Ari Melnick; Adrian Wiestner; Sarah E M Herman
Journal:  Cancer Res       Date:  2017-10-09       Impact factor: 12.701

Review 10.  Targeting Bruton's Tyrosine Kinase in CLL.

Authors:  Inhye E Ahn; Jennifer R Brown
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.